Marshall Stagg, MD
Hematology & Oncology · Baton Rouge, LANPI 1841281573
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,640 of the $18,737 with a category attached, or 72.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.6%. 2025 is the largest year on record at $6,615, 8.6 times the $765 reported in 2019.
Across 577 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- AstraZeneca$2K
- AbbVie$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$687
- Bristol Myers Squibb$617
- plus $9K from 54 others
Across 88 payments — averaging $17,630 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$583K
- Amgen$396K
- Pfizer$157K
- Bristol Myers Squibb$112K
- AstraZeneca$87K
- Novartis$85K
- plus $132K from 6 others
What the payments were for
- Consulting fees$1,5008%
- Food & beverage$13,64073%
- Education$9165%
- Other$2,68114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,737 in reported general payments places this provider in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $752,382 |
| PomalystPomalidomide | 16 | $371,607 |
| XtandiEnzalutamide | 26 | $359,214 |
| Lenalidomide | 18 | $236,244 |
| CalquenceAcalabrutinib Maleate | 14 | $213,125 |
| KisqaliRibociclib Succinate | 14 | $194,563 |
| SprycelDasatinib | 12 | $111,924 |
| Imatinib Mesylate | 25 | $45,178 |
| Abiraterone Acetate | 12 | $18,588 |
| XareltoRivaroxaban | 18 | $10,501 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,646 |
| Fentanyl | 21 | $1,686 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 97 | $1,551 |
| Dexamethasone | 34 | $1,120 |
| Hydroxyurea | 22 | $782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $617 | $752,38239 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $687 | $483,53028 claims |
| Astellas Pharma US IncXtandi | $290 | $359,21426 claims |
| AstraZenecaCalquence, Symbicort | $1,968 | $215,77126 claims |
| NovartisKisqali | $3,863 | $194,56314 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $183 | $18,58812 claims |
| Johnson & JohnsonXarelto | $1,022 | $10,50118 claims |
| Lilly USA, LLCOlanzapine | $22 | $22126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$2M
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Andrew DalovisioBaton Rouge$128K
- Greg BizetteBaton Rouge$32K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
- Pedro BarataNew Orleans$928K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.